Transgene SA (TNG) - Total Liabilities
Based on the latest financial reports, Transgene SA (TNG) has total liabilities worth €17.09 Million EUR (≈ $19.98 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Transgene SA - Total Liabilities Trend (1997–2025)
This chart illustrates how Transgene SA's total liabilities have evolved over time, based on quarterly financial data. See TNG working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Transgene SA Competitors by Total Liabilities
The table below lists competitors of Transgene SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Azkoyen
MC:AZK
|
Spain | €71.89 Million |
|
Ard Grup Bilisim Teknolojileri AS
IS:ARDYZ
|
Turkey | TL2.11 Billion |
|
Exotic Food Public Company Limited
BK:XO
|
Thailand | ฿312.77 Million |
|
Vertical Aerospace Ltd
NYSE:EVTL
|
USA | $210.42 Million |
|
Daewonkangup
KO:000430
|
Korea | ₩719.09 Billion |
|
Axiom Intelligence Acquisition Corp 1 Class A Ordinary Shares
NASDAQ:AXIN
|
USA | $8.20 Million |
|
Nam Kim Steel JSC
VN:NKG
|
Vietnam | ₫8.86 Trillion |
|
Icelandic Salmon As
OL:ISLAX
|
Norway | Nkr153.36 Million |
Liability Composition Analysis (1997–2025)
This chart breaks down Transgene SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Transgene SA stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Transgene SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Transgene SA (1997–2025)
The table below shows the annual total liabilities of Transgene SA from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €17.09 Million ≈ $19.98 Million |
-36.63% |
| 2024-12-31 | €26.97 Million ≈ $31.53 Million |
-8.90% |
| 2023-12-31 | €29.61 Million ≈ $34.61 Million |
+3.53% |
| 2022-12-31 | €28.59 Million ≈ $33.43 Million |
-17.42% |
| 2021-12-31 | €34.63 Million ≈ $40.48 Million |
-1.63% |
| 2020-12-31 | €35.20 Million ≈ $41.16 Million |
-29.28% |
| 2019-12-31 | €49.78 Million ≈ $58.20 Million |
-30.71% |
| 2018-12-31 | €71.84 Million ≈ $83.99 Million |
-1.29% |
| 2017-12-31 | €72.78 Million ≈ $85.09 Million |
-4.79% |
| 2016-12-31 | €76.45 Million ≈ $89.37 Million |
+2.86% |
| 2015-12-31 | €74.32 Million ≈ $86.89 Million |
+7.54% |
| 2014-12-31 | €69.11 Million ≈ $80.80 Million |
-0.16% |
| 2013-12-31 | €69.23 Million ≈ $80.93 Million |
+13.70% |
| 2012-12-31 | €60.89 Million ≈ $71.18 Million |
+16.71% |
| 2011-12-31 | €52.17 Million ≈ $60.99 Million |
+30.20% |
| 2010-12-31 | €40.07 Million ≈ $46.84 Million |
+33.11% |
| 2009-12-31 | €30.10 Million ≈ $35.19 Million |
-7.16% |
| 2008-12-31 | €32.42 Million ≈ $37.91 Million |
+86.58% |
| 2007-12-31 | €17.38 Million ≈ $20.32 Million |
+27.54% |
| 2006-12-31 | €13.63 Million ≈ $15.93 Million |
+20.92% |
| 2004-12-31 | €11.27 Million ≈ $13.17 Million |
-0.27% |
| 2003-12-31 | €11.30 Million ≈ $13.21 Million |
-3.20% |
| 2002-12-31 | €11.67 Million ≈ $13.65 Million |
-8.71% |
| 2001-12-31 | €12.79 Million ≈ $14.95 Million |
-2.76% |
| 2000-12-31 | €13.15 Million ≈ $15.37 Million |
+15.22% |
| 1999-12-31 | €11.41 Million ≈ $13.34 Million |
+0.77% |
| 1998-12-31 | €11.33 Million ≈ $13.24 Million |
+19.61% |
| 1997-12-31 | €9.47 Million ≈ $11.07 Million |
-- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more